Ascletis Pharma, Inc.

Among Chinese developers of weight management medicines presenting at the June 20–23 American Diabetes Association (ADA) congress, Sciwind Biosciences and Laekna Therapeutics appeared to be the stand-

Sagimet Bioscience’s denifanstat has met all primary, key secondary and secondary endpoints in a Phase III clinical trial in China for the treatment of moderate-to-severe acne vulgaris conducted by gr

Ascletis Pharma only joined the obesity field last September but has just presented early data for what could be a best-in-class oral GLP-1 agonist. Data from the Phase Ib MAD study show the Hong Kong

Viking Therapeutics, Inc. now looks poised to win the first round in a string of legal actions it has taken against Chinese firm Ascletis Pharma, Inc. , in which the US biotech alleged infringement